- Home
- EXEL vs NCLH Comparison
EXEL vs NCLH Comparison
Compare EXEL & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- NCLH
- Stock Information
- Founded
- EXEL 1994
- NCLH 1966
- Country
- EXEL United States
- NCLH United States
- Employees
- EXEL N/A
- NCLH N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- NCLH Marine Transportation
- Sector
- EXEL Health Care
- NCLH Consumer Discretionary
- Exchange
- EXEL Nasdaq
- NCLH Nasdaq
- Market Cap
- EXEL 10.4B
- NCLH 11.5B
- IPO Year
- EXEL 2000
- NCLH 2013
- Fundamental
- Price
- EXEL $37.88
- NCLH $25.67
- Analyst Decision
- EXEL Buy
- NCLH Buy
- Analyst Count
- EXEL 21
- NCLH 19
- Target Price
- EXEL $43.65
- NCLH $28.22
- AVG Volume (30 Days)
- EXEL 2.4M
- NCLH 13.1M
- Earning Date
- EXEL 10-28-2025
- NCLH 10-30-2025
- Dividend Yield
- EXEL N/A
- NCLH N/A
- EPS Growth
- EXEL 81.76
- NCLH 61.59
- EPS
- EXEL 2.08
- NCLH 1.54
- Revenue
- EXEL $2,230,005,000.00
- NCLH $9,560,994,000.00
- Revenue This Year
- EXEL $9.24
- NCLH $8.20
- Revenue Next Year
- EXEL $13.04
- NCLH $10.43
- P/E Ratio
- EXEL $18.24
- NCLH $16.66
- Revenue Growth
- EXEL 10.73
- NCLH 5.22
- 52 Week Low
- EXEL $25.12
- NCLH $14.21
- 52 Week High
- EXEL $49.62
- NCLH $29.29
- Technical
- Relative Strength Index (RSI)
- EXEL 44.99
- NCLH 60.95
- Support Level
- EXEL $36.23
- NCLH $23.95
- Resistance Level
- EXEL $38.95
- NCLH $25.59
- Average True Range (ATR)
- EXEL 0.85
- NCLH 0.72
- MACD
- EXEL 0.13
- NCLH 0.03
- Stochastic Oscillator
- EXEL 60.66
- NCLH 80.76
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.